While many rang in 2026 with another countdown as the ball dropped, the Nashville Zoo was having its own New Year’s ...
Aardvark Therapeutics, Inc. (NASDAQ: AARD) is a clinical-stage biopharmaceutical company developing small-molecule therapeutics designed to suppress hunger for Prader-Willi Syndrome (PWS) and ...
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate ...
Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance to ...
Aardvark Therapeutics announces IPO pricing at $16 per share, aiming to raise approximately $94.2 million for metabolic disease research. Aardvark Therapeutics, Inc., a clinical-stage ...
Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome (PWS), with meaningful reductions in hyperphagia (up to a 16 ...
Aardvark is also developing ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, with a goal of addressing some of the limitations of currently marketed GLP-1 therapies for the ...
Clinical trial sites in Canada and the United Kingdom have received regulatory clearance to enroll All patients who have completed HERO trial to date have successfully enrolled and remain in the Open ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results